Cite
MLA Citation
M Soubrier et al.. “SAT0117 Retention rates of adalimumab, etanercept, and infliximab as 1st- or 2nd-line biotherapy for rheumatoid arthritis patients in daily practice in auvergne.” Annals of the rheumatic diseases, vol. 76, n.d., p. 813. http://access.bl.uk/ark:/81055/vdc_100135163270.0x000061